E-ISSN 2636-865X
Research Article
The Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraine
1 Ağrı Devlet Hastanesi, Nöroloji, Ağrı, Türkiye  
2 Ege Üniversitesi Tıp Fakültesi, Nöroloji, İzmir, Türkiye  
3 Ege Üniversitesi Tıp Fakültesi, Nöroloji Anabilimdalı, İzmir, Turkey  
Neurol Sci Neurophysiol 2015; 32: 539-548

Key Words: Onabotulinum toxin-A,resistant chronic migraine, quality of life

Introduction: Resistant chronic migraine (RCM) causes a considerable decline in the quality of life and work efficiency of the patients and ultimately might even decrease their socio-economic level because of severe and permanent headaches. In addition, migraine attacks force patients to rush to the emergency rooms, which leads to overcrowding and exhaustion of medical resources. In this study, the effect of onabotulinum toxin A (OBoNT-A) treatment was assessed in terms of efficiency and the quality of life retrospectively at patients with RCM.


Method: 15 patients with RCM who were given 155 IU OBoNT-A treatment twice in 12 weeks have been studied retrospectively in terms of change of headache frequency, severity, and the health related quality of life scores (physical function, physical restriction, pain, general health, vitality, social function, emotion and mental health categories) for 24 weeks. Response to treatment is identified as ≥30% decrease in headache frequency while the change in the quality of life was determined with short form-36 before and after treatment.


Findings: Average headache frequency was 26.3 day/month before treatment. After 24 weeks, 93% of the patients were responsive to the treatment. After OBoNT-A treatment average headache frequency decreased to 16,6 day/month in 12 weeks and to 17,8 day/month in 24 weeks (p<0.001). Average health related quality of life scores before treatment were under 50%, while all the health related quality of life scores improved after treatment(p<0.001). At the end of 24 weeks, headache severity significantly decreased (p<0.001).


Conclusion: OBoNT-A is an effective treatment in patients with RCM and it must be considered a first line treatment for RCM patients considering the cost-effectiveness researches.

Key Words
Author's Corner
AVES | Copyright © 2019 Latest Update: 24.06.2019